ACR Convergence 2020—At two plenary sessions, speakers highlighted key findings, including results on the QTc interval in patients on hydroxychloroquine, and data from a study on denosumab vs. alendronate for glucocorticoid-induced osteoporosis. The QTc Interval & Hydroxychloroquine The safety profile and optimal dosing of hydroxychloroquine has been a topic for decades because it is known…
Preclinical models have provided important insights into the pathogenesis of OA and potential pathways for therapeutic intervention, including adenosine. Ticagrelor and clopidogrel are both used in patients with coronary artery disease, but only ticagrelor increases extracellular adenosine levels. In this study, treatment with ticagrelor was associated with a 29% lower risk of developing OA than treatment with clopidogrel over five years of follow-up.
Pain is the main reason patients with osteoarthritis (OA) seek medical help because of the substantial burden it imposes and its impact on quality of life. Pain can actually change the way the central nervous system works. This central sensitization results in more pain with less provocation. And according to results from an observational study…
A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…
(Reuters Health)—Patients with a degenerative meniscus tear who get arthroscopic partial meniscectomy have similar five-year outcomes and increased risk of radiographic knee osteoarthritis (OA) as without surgery, a small study suggests. Researchers in Finland randomly assigned 146 adults with degenerative meniscus tear confirmed by magnetic resonance imaging (MRI) to receive either arthroscopic partial meniscectomy (APM)…
Physical inactivity significantly affects disease burden and reduces the overall quality of life in patients with knee osteoarthritis (OA), according to a study from Losina et al. The researchers calculated the total quality-adjusted life-years lost for U.S. patients with OA due to inactivity.
NEW YORK (Reuters Health)—Using bisphosphonates for several years is associated with increasing brittleness and decreasing toughness of bone, according to a new review. “Long-term treatment with bisphosphonates can have negative side effects in some people because of their effects on bone toughness [toughness = the energy that bone tissue can absorb before cracking],” David B….
In a clinical trial, researchers compared the efficacy of abaloparatide with alendronate in reducing the risk of fracture among postmenopausal women with osteoporosis. The findings suggest initial treatment with abaloparatide may result in greater vertebral fracture reduction than alendronate…
NEW YORK (Reuters Health)—Interleukin (IL) 1 beta is a key player in the osteoarthritis (OA) inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of data from the CANTOS trial.1 CANTOS participants who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip…
NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…